دورية أكاديمية
أعرض في EDS

Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization.

التفاصيل البيبلوغرافية
العنوان: Management of type 1 immediate hypersensitivity reactions to antituberculosis drug: succesful desensitization.
المؤلفون: Katran ZY; Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey. zynpyegin@hotmail.com., Bulut İ; Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey., Babalik A; Department of Chest Diseases, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey., Keren M; Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Turkey.
المصدر: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology [Allergy Asthma Clin Immunol] 2022 Nov 21; Vol. 18 (1), pp. 97. Date of Electronic Publication: 2022 Nov 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Country of Publication: England NLM ID: 101244313 Publication Model: Electronic Cited Medium: Print ISSN: 1710-1484 (Print) Linking ISSN: 17101484 NLM ISO Abbreviation: Allergy Asthma Clin Immunol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: Oct. 2009- : London : BioMed Central
Original Publication: Hamilton, Ont. : BC Decker, c2004-
مستخلص: Objective: In this study, it was aimed to investigate the prevalence of type 1 hypersensitivity reaction under tuberculosis treatment and the management of hypersensitivity.
Methods: The study is a case series. All of the patients who were hospitalized between 01.02.2015-01.05.2021 were examined. All patients who developed a drug-induced type 1 immediate hypersensitivity reaction were included. Antituberculosis drugs were given with the protocol made by Buhari et al. However, unlike what is stated in the protocol, pyrazinamide was given last during the administration of the drugs.
Results: 2677 patients received inpatient tuberculosis treatment; type 1 immediate hypersensitivity reactions were seen in 94 (3.5%) patients. Due to missing data in the file, 81 patients were included in the study. 44 (54.3%) of the cases were women; mean age (mean ± SD) 50.7 ± 17.69 years; 76 (93.8%) of them are citizens of the Republic of Turkey; 58 (71.6%) of them were diagnosed bacteriologically; 65 (80.2%) of them were pulmonary tuberculosis. The most common skin finding was urticaria in 49 (60.5%). The drug responsible for the most common reaction was pyrazinamide. In 49 (60.5%) cases, drugs were given by desensitization and it was successful. The duration of treatment was 7.91 ± 2.5 months (6-18 months). When evaluated in terms of treatment results, 68 (84%) patients successfully completed the treatment.
Conclusion: Our study is the largest series of patients who developed type 1 immediate hypersensitivity reaction while receiving antituberculosis treatment. A practical, easy desensitization scheme has been shared.
(© 2022. The Author(s).)
References: Curr Opin Allergy Clin Immunol. 2018 Aug;18(4):333-341. (PMID: 29901473)
Allergy. 2010 Nov;65(11):1357-66. (PMID: 20716314)
J Allergy Clin Immunol Pract. 2021 Sep;9(9):3442-3449.e3. (PMID: 33872812)
Am J Respir Crit Care Med. 2002 Oct 1;166(7):916-9. (PMID: 12359646)
Clin Exp Allergy. 2022 Mar;52(3):375-386. (PMID: 34939251)
Med J Malaysia. 2007 Jun;62(2):143-6. (PMID: 18705448)
Pediatr Allergy Immunol. 2014 Jun;25(4):404-5. (PMID: 24417546)
Indian Dermatol Online J. 2020 Mar 09;11(2):177-181. (PMID: 32477975)
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7. (PMID: 12569078)
Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. (PMID: 12588714)
Ann Allergy Asthma Immunol. 2015 Jul;115(1):39-44. (PMID: 25981840)
Int Arch Allergy Immunol. 2006;140(1):20-6. (PMID: 16514245)
Saudi Pharm J. 2014 Apr;22(2):83-94. (PMID: 24648818)
Allergol Immunopathol (Madr). 2009 Nov-Dec;37(6):336-8. (PMID: 19875222)
Int J Tuberc Lung Dis. 2007 Aug;11(8):868-75. (PMID: 17705952)
Respir Med. 2019 Feb;147:44-50. (PMID: 30704698)
Lancet. 2019 Apr 20;393(10181):1642-1656. (PMID: 30904262)
Eur Respir J. 1996 Oct;9(10):2026-30. (PMID: 8902462)
Allergy. 2012 May;67(5):647-52. (PMID: 22435670)
Allergol Immunopathol (Madr). 2011 Sep-Oct;39(5):311-2. (PMID: 21489680)
تواريخ الأحداث: Date Created: 20221122 Latest Revision: 20221125
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9682841
DOI: 10.1186/s13223-022-00737-4
PMID: 36414980
قاعدة البيانات: MEDLINE
الوصف
تدمد:1710-1484
DOI:10.1186/s13223-022-00737-4